CareDx Informed Natera And The Court, Since August 2023, CareDx Has Utilized A New AlloSure Process That It Believes Does Not Infringe On The '544 Patent.
Portfolio Pulse from Benzinga Newsdesk
CareDx has responded to Natera's motion for an injunction related to patent 11,111,544, stating that it no longer uses the process in question and believes the motion is irrelevant. CareDx asserts that the injunction will not impact its business or patient access to its products.
May 29, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CareDx has responded to Natera's motion for an injunction, stating that it no longer uses the process in question and believes the motion is irrelevant. The company asserts that the injunction will not impact its business or patient access to its products.
CareDx's response indicates that the injunction motion will not affect its business operations or patient access to its products. The company has already switched to a new process that it believes does not infringe on the patent in question.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Natera has filed a motion for an injunction against CareDx related to patent 11,111,544. CareDx claims the motion is irrelevant as it no longer uses the process in question and believes the injunction will not impact its business.
Natera's motion for an injunction may not have a significant impact on its stock price in the short term as CareDx claims the motion is irrelevant and will not affect its business operations.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80